Here's the bit -- from local Philly.com sources:
. . . .Novira Therapeutics Inc., Doylestown, a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus infection, has named Roger J. Pomerantz chair of its scientific advisory board. In this role, he also will function as a senior adviser to the company. Pomerantz is president, chief executive officer, and chairman of Seres Health and was senior vice president and worldwide head of licensing and acquisitions at Merck & Co. Inc., where he oversaw all licensing and acquisitions at Merck Research Laboratories. . . .
So it goes -- he's a very talented guy.
1 comment:
Those Forest guys -- ex S-P boys. . .
Are jerks -- to a person.
Agreed.
But their time is drawing to an end, nationwide.
As my new post indicates, insurers and the government are putting an end to the reimbursement for the worst of this nonsense. When no efficiacy improvement is made, no additional reimbursement will be allowed, from version switching. . . . eliminate the incentive, and the practice dies.
Namaste -- do stop back!
Post a Comment